Cargando…

Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants

Detalles Bibliográficos
Autores principales:	Su, Shan, Shao, Yiming, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971202/ https://www.ncbi.nlm.nih.gov/pubmed/33635184 http://dx.doi.org/10.1080/22221751.2021.1896956

Ejemplares similares

Ring vaccination of COVID‐19 vaccines in medium‐ and high‐risk areas of countries with low incidence of SARS‐CoV‐2 infection
por: Xu, Wei, et al.
Publicado: (2021)

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests
por: Eyal, Nir, et al.
Publicado: (2021)

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
por: Su, Shan, et al.
Publicado: (2022)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Evaluation of vaccine effectiveness against SARS‐CoV‐2 variants by serological epitope profiling
por: Li, Cheng, et al.
Publicado: (2023)

Multicomponent vaccines to fight SARS-CoV-2 variants of concern
por: Cassone, Antonio, et al.
Publicado: (2021)

The challenge of emerging SARS-CoV-2 mutants to vaccine development
por: Li, Rong, et al.
Publicado: (2021)

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics
por: Su, Shan, et al.
Publicado: (2021)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Renaming the SARS‐CoV‐2 Omicron sublineages as SARS‐CoV‐3 is contrary to nomenclature standards based on evolutionary and serological evidence
por: Qi, Zhongtian, et al.
Publicado: (2022)

Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Wang, Fuzhen, et al.
Publicado: (2021)

Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
por: Rahman, Smaranika, et al.
Publicado: (2022)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Park, Su-Jin, et al.
Publicado: (2020)

Current vaccine strategies against SARS-CoV-2: Promises and challenges
por: Kurup, Drishya, et al.
Publicado: (2022)

Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges
por: Quadir, Neha, et al.
Publicado: (2022)

Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants
por: Maltezou, Helena C., et al.
Publicado: (2022)

The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
por: Shalash, Ahmed O., et al.
Publicado: (2022)

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
por: Rayati Damavandi, Amirmasoud, et al.
Publicado: (2022)

Approved mRNA Vaccines for SARS-CoV-2
por: Faiman, Beth
Publicado: (2021)

Challenges and developments in universal vaccine design against SARS-CoV-2 variants
por: Zhao, Fangxin, et al.
Publicado: (2022)

The mysterious origins of the Omicron variant of SARS-CoV-2
por: Du, Pei, et al.
Publicado: (2022)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

Is the Omicron variant of SARS-CoV-2 coming to an end?
por: Zhao, Yingjie, et al.
Publicado: (2022)

Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?
por: Bauer, Lisa, et al.
Publicado: (2023)

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
por: Ma, Cuiqing, et al.
Publicado: (2020)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

Role of Omicron variant of SARS-CoV-2 in children in Germany
por: Bittmann, Stefan
Publicado: (2022)

SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant
por: Berkhout, Ben, et al.
Publicado: (2022)

Routine Antigen Testing Is Not a Substitute for Health Care Worker Vaccination against SARS-CoV-2
por: Sexton, Mary Elizabeth, et al.
Publicado: (2021)

A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
por: Rabaan, Ali A., et al.
Publicado: (2022)

SARS-CoV-2 diagnostics: Some reflections on current assays
por: Antonelli, Guido, et al.
Publicado: (2021)

The challenge of asymptomatic SARS-CoV-2 transmission in care homes
por: Belmin, Joël, et al.
Publicado: (2021)

Disease Prevalence Matters: Challenge for SARS-CoV-2 Testing
por: Lau, Chin-Shern, et al.
Publicado: (2021)

Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
por: Hossain, Md. Jamal, et al.
Publicado: (2022)

Inactivated SARS-CoV-2 vaccine for people with HIV
por: Wolday, Dawit, et al.
Publicado: (2022)

Is there a post-SARS-CoV-2 vaccination dementia?
por: Fiorini, Ana C., et al.
Publicado: (2022)

SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia
por: Ghiffari, Ahmad, et al.
Publicado: (2022)

A Commentary on “Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt” (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_grmuehn696d1kjdnatcclip759